Amazon profit crushes estimates as cloud service revenue jumps | Reuters
Amazon.com Inc's ( AMZN.O ) quarterly profit and revenue topped analysts' expectations by a wide margin as the Prime loyalty program helped the online retail giant attract more customers and revenue surged in its cloud services business. Shares of the world's biggest online retailer jumped nearly 13 percent to $679 in extended trading on Thursday
Amazon.com Inc's (AMZN.O) quarterly profit and revenue topped analysts' expectations by a wide margin as the Prime loyalty program helped the online retail giant attract more customers and revenue surged in its cloud services business.
Shares of the world's biggest online retailer jumped nearly 13 percent to $679 in extended trading on Thursday.
Amazon has seen strong growth in subscribers to its Prime loyalty program, which offers one-hour delivery, original TV programming and access to its digital entertainment products such as Prime Music and Prime Video for an annual fee of $99.
The company recently launched a monthly subscription to the program for $10.99. Amazon has also said it plans to offer its video streaming service for a monthly fee of $8.99.
Amazon's net sales in North America, its biggest market by revenue, increased 26.8 percent to $17 billion in the first quarter.
Revenue from its cloud services business, Amazon Web Services, surged 63.9 percent to $2.57 billion. The unit, Amazon's fastest growing business, is seen as the next driver of growth for the company.
Amazon reported net income of $513 million, or $1.07 per share, for the quarter ended March 31. The company had a loss of $57 million, or 12 cents per share, a year earlier.
Net sales surged 28.2 percent to $29.13 billion.
Analysts on average had expected a profit of 58 cents per share and revenue of $27.98 billion, according to Thomson Reuters I/B/E/S.
(Reporting by Narottam Medhora in Bengaluru; Editing by Kirti Pandey)
This story has not been edited by Firstpost staff and is generated by auto-feed.
By Deena Beasley and Julie Steenhuysen (Reuters) -U.S. regulators on Monday approved Biogen Inc's aducanumab as the first treatment to attack a likely cause of Alzheimer's disease despite controversy over whether the clinical evidence proves the drug works. Aducanumab aims to remove sticky deposits of a protein called amyloid beta from the brains of patients in earlier stages of Alzheimer's in order to stave off its ravages, which include memory loss and the inability to care for one's self.
By Arpan Varghese (Reuters) - Gold held on to gains as the dollar slid on Monday, with investors awaiting U.S. inflation data later this week for clarity on when the Federal Reserve might start tapering economic support measures. Spot gold rose 0.3% to $1,895.77 per ounce by 01:42 p.m
By Aftab Ahmed NEW DELHI (Reuters) - India may raise spending on COVID-19 shots by over a quarter this fiscal year to up to 450 billion rupees ($6.18 billion) from its budgeted amount, two government sources told Reuters after the prime minister offered free doses to all adults.